Singapore Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis

Singapore Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis

The Singapore Autosomal Dominant Polycystic Kidney Disease Therapeutics Market is at around US $1 Mn in 2022 and is projected to reach US $2 Mn in 2030, exhibiting a CAGR of 6.4% during the forecast period.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is an inherited condition characterized by gene mutations (PKD1 and PKD2), causing the formation of fluid-filled cysts in multiple organs, particularly the kidneys, leading to their enlargement (renomegaly). This progression often results in kidney failure (ESKD). Common symptoms include pain, recurring infections, and fatigue. While incurable, managing ADPKD primarily focuses on preventing complications and addressing symptoms. Tolvaptan (Jinarc), developed by Otsuka Pharmaceuticals and approved for ADPKD treatment, acts as a vasopressin blocker, reducing cyst formation in specific patients. Pain management, lifestyle adjustments, and various medications targeting related issues like hypertension provide additional treatment options.

The evidence suggests that 1 in 756 individuals is estimated to carry at least one mutation in the ADPKD gene in Singapore. The anticipated prevalence is between 1/4000 and 1/10,000 people. The market is therefore driven by major factors like the rising prevalence of cases due to demographic shifts and better survival rates, government initiatives and supportive policies, and strong healthcare infrastructure in the industry. However, conditions such as high costs of available treatment, a fragmented patient pool, and others hinder the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Surge in the prevalence of ADPKD: According to epidemiological data gathered by the National Kidney Foundation (NKF) in Singapore, every 1 in 756 individuals is estimated to carry at least one mutation in the ADPKD gene. The expected prevalence is around 1/4000–1/10,000 individuals in Singapore. More than 3,00,000 people are currently living with CKD. These factors result in patients requiring advanced treatments, resulting in the growth of the market.

Government initiatives: Government initiatives aimed at addressing rare diseases and chronic conditions, involving funding allocations like the Rare Disease Fund (RDF) for patients and research and development, pave the way for future progress in ADPKD treatment. This could potentially enhance medication accessibility through the expansion of healthcare programs, allowing market expansion.

Strong healthcare infrastructure: Singapore’s robust healthcare system includes modern medical institutes and a proficient nephrology workforce, ensuring ADPKD patients have access to specialized care. This enables early identification, personalised treatment strategies, and innovative ADPKD treatments, fostering expansion in the market.

Increased awareness: Increasing public awareness and educational campaigns promote early diagnosis, enabling timely interventions and potentially widening the market for treatments focused on slowing the advancement of the disease. Group such as the Singapore Society of Nephrology (SSN) work towards improving patient access and care, influencing evidence-based policy decisions by gathering data that propel the therapeutics market.

Market Restraints

High costs of treatment: Innovative treatments for ADPKD, notably gene therapy approaches, may incur significant costs. Despite Singapore's strong healthcare system and governmental aid, patients might encounter financial challenges. This situation could restrict treatment access and hinder market advancement.

Fragmented patient pool: The limited population size in Singapore and the potentially smaller number of individuals affected by ADPKD could lead to a fragmented market. This scenario might dissuade pharmaceutical companies from making substantial investments in developing or promoting new therapies tailored for ADPKD.

Limited local research and development: In contrast to other significant markets, Singapore’s involvement dedicatedly in ADPKD research might be relatively limited, which could slow down the development and accessibility of new treatment options for Singaporean patients. This situation restricts market diversity and the potential for innovation.

Healthcare Policies and Regulatory Landscape

Singapore's healthcare policy and regulatory landscape encompass several key bodies and organizations. The Ministry of Health (MOH) serves as the primary authority overseeing healthcare regulations and licensing in the country. It's responsible for formulating national health strategies, driving healthcare reforms, and supervising healthcare service delivery across Singapore.

Obtaining a license for healthcare products in Singapore mandates compliance with regulations set by the MOH. Companies dealing with pharmaceuticals and medical devices need registration and marketing approval from the Health Sciences Authority (HSA), an entity operating under the MOH's statutory board. This process involves providing technical and scientific data to validate the safety, quality, and efficacy of the products.

The MOH regularly evaluates Singapore's healthcare system against global benchmarks and conducts annual patient experience surveys. Additionally, it introduced the Licensing Experimentation and Adaptation Program, functioning as a regulatory "sandbox" to explore and understand emerging healthcare innovations. Both the public and private healthcare sectors in Singapore offer diverse prospects for businesses within the healthcare industry

Competitive Landscape

Key Players

• Alebund Pharmaceutical
• Regulus Therapeutics
• Kadmon Pharmaceuticals
• Reata Pharmaceuticals
• Galapagos NV
• Anakuria Therapeutic
• AceLink Therapeutics, Inc
• Sanofi
• Xortx Therapeutics
• Chinook Therapeutics